Special Issue "Drug Candidates Target HTLV-1 and HTLV-1-Related Diseases"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 25 March 2024 | Viewed by 1032

Special Issue Editors

Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil
Interests: HTLV-1; adult T-cell leukemia/Lymphoma (ATLL); HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP); Immunology
Department of Infectious Disease, Imperial College London, London, UK
Interests: HTLV-1; integrase; integration; intasome assembly; PP2A-B56; integrase inhibitors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Estimates indicate that more than 10 million individuals live with human T-cell lymphotropic virus type 1 (HTLV-1) worldwide. HTLV-1 is a retrovirus responsible for highly aggressive neoplastic diseases, such as adult T-cell leukemia/Lymphoma (ATLL), and inflammatory diseases as HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP). Despite the advances in understanding the pathogenesis of HTLV-1, there is still a need to develop more effective therapies. ATLL carriers have a poor prognosis for disease evolution and a low life expectancy. These patients usually receive combined chemotherapy, but the infected cells are resistant to a large part of the cell death-inducing agents. Moreover, asymptomatic people living with HTLV-1 or carriers of HTLV-1-related diseases are treated against some symptoms using corticosteroids. However, some new compounds or drug repositioning and immunotherapy have been described with treatment promising for HTLV-1-related disease. In addition, there is promise to use antiretrovirals as a pre-exposure prophylaxis. The aim of this Special Issue is to compilate the new findings in this area.

Dr. Juliana Echevarria Neves de Lima
Dr. Goedele N. Maertens
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • HTLV-1
  • adult T-cell leukemia/Lymphoma (ATLL)
  • HTLV-1-associated myelopathic/tropical spastic paraparesis (HAM/TSP)
  • treatment
  • new compounds
  • drug repositing and immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


25 pages, 2728 KiB  
New Perspectives about Drug Candidates Targeting HTLV-1 and Related Diseases
Pharmaceuticals 2023, 16(11), 1546; https://doi.org/10.3390/ph16111546 - 02 Nov 2023
Viewed by 544
Among the human T-lymphotropic virus (HTLV) types, HTLV-1 is the most prevalent, and it has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection syndrome or disseminated strongyloidiasis. There is currently no globally standard first-line treatment for HTLV-1 infection and [...] Read more.
Among the human T-lymphotropic virus (HTLV) types, HTLV-1 is the most prevalent, and it has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection syndrome or disseminated strongyloidiasis. There is currently no globally standard first-line treatment for HTLV-1 infection and its related diseases. To address this, a comprehensive review was conducted, analyzing 30 recent papers from databases PubMed, CAPES journals, and the Virtual Health Library (VHL). The studies encompassed a wide range of therapeutic approaches, including antiretrovirals, immunomodulators, antineoplastics, amino acids, antiparasitics, and even natural products and plant extracts. Notably, the category with the highest number of articles was related to drugs for the treatment of ATLL. Studies employing mogamulizumab as a new perspective for ATLL received greater attention in the last 5 years, demonstrating efficacy, safe use in the elderly, significant antitumor activity, and increased survival time for refractory patients. Concerning HAM/TSP, despite corticosteroid being recommended, a more randomized clinical trial is needed to support treatment other than corticoids. The study also included a comprehensive review of the drugs used to treat disseminated strongyloidiasis in co-infection with HTLV-1, including their administration form, in order to emphasize gaps and facilitate the development of other studies aiming at better-directed methodologies. Additionally, docking molecules and computer simulations show promise in identifying novel therapeutic targets and repurposing existing drugs. These advances are crucial in developing more effective and targeted treatments against HTLV-1 and its related diseases. Full article
(This article belongs to the Special Issue Drug Candidates Target HTLV-1 and HTLV-1-Related Diseases)
Show Figures

Figure 1

Back to TopTop